Besufetamig  (Synonyms: ONO-4685)

Besufetamig is a bispecific antibody targeting programmed cell death 1 (PD-1) and CD3ε chain. Besufetamig modulates the activity of immune cells, exerting immunosuppressive and antineoplastic activities. Besufetamig is promising for research of cancers^[1].

immunoglobulin (H-gamma1_L-kappa)_(H-gamma1_L-kappa)

Human IgG1 kappa, Isotype Control

Human

PD-1 & CD3E

5133  [NCBI] & 916  [NCBI]

Q15116 & P07766

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.01 kDa

3037124-22-1

Liquid

Colorless to light yellow

[Besufetamig]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa

• 
  Immobilized PD-1 Protein, Human (143a.a, HEK293, His, HY-P7396) can bind Besufetamig. The EC₅₀ for this effect is 5.266 ng/mL.
• 
  Immobilized CD3 epsilon Protein, Human (HEK293, His, HY-P70506) can bind Besufetamig. The EC₅₀ for this effect is 41.78 ng/mL.
• 
  Flow Cytometry analysis of Hela cells labelling PD-1 (red) with Besufetamig (anti-PD-1) (HY-P991122, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99991, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Flow Cytometry analysis of Jurkat cells labelling CD3E (red) with Besufetamig (anti-CD3E) (HY-P991122, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99991, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. World Health Organization. WHO Drug Information: Volume 38[M]. World Health Organization, 2024.